Sample & Assay Technologies -1- QIAGEN – Sample and Assay Technologies Société Générale Corporate & Investment Banking The European Mid & Small Caps Conference London, November 20, 2007 Dr. Joachim Schorr Senior Vice President Global Research & Development
27
Embed
QIAGEN – Sample and Assay Technologies...Global In Vitro Diagnostics Market By Segment (2006E) MDx: Fastest Growing Segment in In-Vitro Diagnostics Growth Drivers Note: IVD market
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Sample & Assay Technologies- 1 -
QIAGEN – Sample and Assay Technologies
Société Générale Corporate & Investment BankingThe European Mid & Small Caps Conference
London, November 20, 2007
Dr. Joachim Schorr Senior Vice President Global Research & Development
Sample & Assay Technologies- 2 -
Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and geneticvaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations for certain events including funding, budgets, and others), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, the management of intellectual property, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission (SEC).
Regulation G: The following slides contain certain summary information about QIAGEN N.V.’s sales, gross profit, operating income, net income, and earnings per share for the third quarter 2007, and the comparable period of 2006, which information is presented on a “non-GAAP financial measures” basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN’s press release dated November 5, 2007, for information on the company’s operating income, net income, and earnings per share for these periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company’s reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission.
Forward Looking Statements
Sample & Assay Technologies- 3 -
Revenues: 2006: $ 466 million 03–06 CAGR: 15%Net income: 2006: $ 85 million 03–06 CAGR 22%1
Sales in MDx (run rate Q2 2007): approx. $380 million#1 (excluding blood banking and viral load monitoring)
Sample technologies: proven standard
Assay technologies: unparalleled breadth (>120 assays)PCR and real-time PCR assaysMultiplexing leader: QIAplexLeading in key assay areas (HPV)Broad platform base
Regulated portfolio – global and growing5 FDA (PMA approved or 510k cleared) products38 CE-marked assays, 6 CE-marked sample preparation products9 SFDA approved assays 98 general purpose reagents
Molecular Diagnostics
Growth Drivers
Sample & Assay Technologies- 17 -
Global In Vitro Diagnostics MarketBy Segment (2006E)
MDx: Fastest Growing Segment in In-Vitro Diagnostics
Growth Drivers
Note: IVD market estimates vary by source and range between ~$29B–$35BSource: RBC Capital Markets, Nature Biotechnology (August 2006), Digene internal reports, Recap, Kalorama, BioCentury, L.E.K. Analysis
ClinicalChemistry
CAGR 2.6%Molecular
DiagnosticsUS$ 2.4B
CAGR 17.0%Blood GlucoseCAGR 11.5%
OtherCAGR 3.5%
HematologyCAGR 3.9%
Immuno-assaysCAGR 4.7%
MicrobiologyCAGR 5.7%
HemostasisCoagulation
CAGR 10.2%
Point of CareCAGR 10.9%
In Vitro Diagnostics Estimated market volume: ~US$ 33B (2006)
Revenues excluding the synthetic DNA business unit, sold in Q2 2004
Sample & Assay Technologies- 24 -
30
40
50
60
70
80
90
100
110
2003 2004 2005 2006 2007E
QIAGEN Net Income 2003 – 2007E
US$ millions
QIAGEN – Strong Earnings Engine
US$ 0.32 US$ 0.56EPSAdj.
US$ 0.61-US$ 0.62
US$ 0.46US$ 0.39
All figures excluding acquisition, integration and relocation related charges as well asamortization of acquired IP and equity-based compensation (SFAS 123R)
Financials
CAGR2003-2006 = 22%
Sample & Assay Technologies- 25 -
43%30.643.7Operating income (US$m), adj.2
42%21.931.1Net income (US$m), adj.3
21%0.140.17EPS (US$), adj.3
26%25%Operating margin, adj.2
50%117.9176.6Net sales (US$m)
GrowthQ3 2006Q3 2007
Financial Performance Exceeded Expectations
Third Quarter 2007At a Glance
1 US$172 million using January 31, 2007 foreign currency exchange rates 2 excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and
equity-based compensation (SFAS 123R) 3 excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and
equity-based compensation (SFAS 123R) and including a tax benefit of US$0.02 in EPS in Q3 2007
1
Financials
Sample & Assay Technologies- 26 -
Fourth Quarter and Fiscal Year 2007 Guidance
0.13 – 0.14EPS (US$), adj2
Guidance Q4 20071
QIAGEN Significantly Increases EPS (adj.) Guidance by US$ 0.03
1 based on January 31, 2007 foreign currency exchange rates2 excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and
equity-based compensation (SFAS 123R) 3 excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and
equity-based compensation (SFAS 123R) as well as including a tax benefit of US$0.02in Q3 2007